MedTrace Logo

Sequential Changes of Serum KL-6 Predict Progression in Interstitial Lung Disease

NCT02960672 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2016-11-10

No results posted yet for this study

Summary

Interstitial lung disease is a chronic progressive fibrosis lung disease that with a highly variable clinical process.thence it is significant for the patient to search a convenient and accurate prediction method. The objective of this study was to determine whether peripheral blood biomarkers can predict disease .

Conditions

  • Interstitial Lung Disease, Desquamative

Sponsors & Collaborators

  • The First Affiliated Hospital of Guangzhou Medical University

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2016-10-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02960672 on ClinicalTrials.gov